Algorae Pharmaceuticals (ASX:1AI) has formalised a definitive license and supply agreement with India’s Cadila Pharmaceuticals.
The partnership focuses on the commercialisation of two generic medicines designed to treat cardiovascular and metabolic disorders across the Australia and New Zealand markets.
Under the terms of the deal, Cadila—one of India’s largest private pharmaceutical firms—will manage product development and large-scale manufacturing.
Algorae’s specialised subsidiary, AlgoraeRx, will take the lead on the ground, holding sponsorship with the Therapeutic Goods Administration and overseeing all regulatory submissions and regional marketing efforts.
The collaboration integrates Cadila's vertical manufacturing capabilities with Algorae's growing distribution network, which already includes agreements with Sakar Healthcare and Dr. Reddy’s Laboratories.
While Algorae expands its revenue-generating generic portfolio, the company continues to advance its high-tech R&D.
The partnership aligns with ongoing work at the Peter MacCallum Cancer Centre, where the company recently validated AlgoraeOS Version 2.
The AI-driven platform utilised approximately 10,000 data points to identify synergistic drug combinations, significantly de-risking its therapeutic pipeline.
At the time of reporting, Algorae Pharmaceuticals’ share price was $0.022.